Traders cheer after the company reports upbeat regulatory news. Here's what investors need to know.
News & Analysis: Curis
The biopharma reported second-quarter 2017 earnings and data from a key mid-stage trial.
Cheap stocks are often cheap for a reason, but sometimes the market has mispriced their potential.
The FDA lifts its clinical hold on Curis cancer drug and shares surge on the news.
Curis, Amgen, CytRx, and Novartis could make waves in the biotech sector this morning.
A mixed bag of clinical studies, a highly-awaited FDA panel thumbs-up, and an unwelcome subpoena from the Department of Health and Human Services for one biotech company are this week's top stories.
Curis shares sink after reporting early-stage clinical data involving CUDC-907. Is now the time to buy, or should shareholders stick to the sidelines?
Two positive clinical studies, a partial clinical hold by the FDA, a scrapped phase 2 study, and an expanded strategic partnership to fight obesity are among this week's top stories in the biotech sector.
Curis goes down for the count after the Food and Drug Administration halts enrollment in an early-stage cancer study.
These four stocks could make big moves today. Let's check in on the headlines moving Myriad, Jazz, Curis, and VIVUS.